{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:36Z","timestamp":1792782996517,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20220530154409021"],"award-info":[{"award-number":["JCYJ20220530154409021"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Medical Research Fund","award":["A2403063"],"award-info":[{"award-number":["A2403063"]}]},{"name":"National Natural Science Foundation of China","award":["72274193"],"award-info":[{"award-number":["72274193"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10557-026-07883-6","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:45:46Z","timestamp":1777700746000},"page":"2049-2060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sources of Heterogeneity in the Efficacy of Statins for Primary Prevention of Cardiovascular Diseases: A Systematic Review with Meta-Regression and Meta-Analysis of Within-Study Subgroup Differences"],"prefix":"10.1007","volume":"40","author":[{"given":"Yujun","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongqi","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanbao","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"7883_CR1","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Ong KL, Aali A, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(24)00367-2.","journal-title":"Lancet"},{"key":"7883_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","volume":"37","author":"PM Ridker","year":"2016","unstructured":"Ridker PM, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37:1373\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehw046.","journal-title":"Eur Heart J"},{"key":"7883_CR3","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140:e596\u2013646. https:\/\/doi.org\/10.1161\/CIR.0000000000000678.","journal-title":"Circulation"},{"key":"7883_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"CTT Collaborators","year":"2012","unstructured":"Collaborators CTT, (CTT). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(12)60367-5.","journal-title":"Lancet"},{"key":"7883_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2022.12138","volume":"328","author":"R Chou","year":"2022","unstructured":"Chou R, Cantor A, Dana T, et al. Statin use for the primary prevention of cardiovascular disease in adults: Updated evidence report and systematic review for the US preventive services task force. JAMA. 2022;328:754\u201371. https:\/\/doi.org\/10.1001\/jama.2022.12138.","journal-title":"JAMA"},{"key":"7883_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","volume":"3","author":"MS Sabatine","year":"2018","unstructured":"Sabatine MS, Wiviott SD, Im K, et al. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: A meta-analysis. JAMA Cardiol. 2018;3:823\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2018.2258.","journal-title":"JAMA Cardiol"},{"key":"7883_CR7","doi-asserted-by":"publisher","first-page":"n1537","DOI":"10.1136\/bmj.n1537","volume":"374","author":"T Cai","year":"2021","unstructured":"Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021;374:n1537. https:\/\/doi.org\/10.1136\/bmj.n1537.","journal-title":"BMJ"},{"key":"7883_CR8","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0002-9149(99)00533-0","volume":"84","author":"J Shepherd","year":"1999","unstructured":"Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol. 1999;84:1192\u20137. https:\/\/doi.org\/10.1016\/S0002-9149(99)00533-0.","journal-title":"Am J Cardiol"},{"key":"7883_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/jgs.12660","volume":"62","author":"YM Drewes","year":"2014","unstructured":"Drewes YM, Poortvliet RKE, Blom JW, et al. Homocysteine levels and treatment effect in the prospective study of pravastatin in the elderly at risk. J Am Geriatr Soc. 2014;62:213\u201321. https:\/\/doi.org\/10.1111\/jgs.12660.","journal-title":"J Am Geriatr Soc"},{"key":"7883_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.medj.2022.04.007","volume":"3","author":"T Wilmanski","year":"2022","unstructured":"Wilmanski T, Kornilov SA, Diener C, et al. Heterogeneity in statin responses explained by variation in the human gut microbiome. Med (N Y). 2022;3:388\u2013e4056. https:\/\/doi.org\/10.1016\/j.medj.2022.04.007.","journal-title":"Med (N Y)"},{"key":"7883_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758\u201364. https:\/\/doi.org\/10.1093\/aje\/kwv254.","journal-title":"Am J Epidemiol"},{"key":"7883_CR12","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"7883_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"7883_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"7883_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s13142-016-0386-8","volume":"6","author":"SI Bangdiwala","year":"2016","unstructured":"Bangdiwala SI, Bhargava A, O\u2019Connor DP, et al. Statistical methodologies to pool across multiple intervention studies. Transl Behav Med. 2016;6:228\u201335. https:\/\/doi.org\/10.1007\/s13142-016-0386-8.","journal-title":"Transl Behav Med"},{"key":"7883_CR16","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing Meta-Analysis With R: A Hands-On Guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P. A FT, et al. Doing meta-analysis with R: A hands-on guide. 1st ed. Boca Raton, FL and London: Chapman & Hall\/CRC; 2021.","edition":"1"},{"key":"7883_CR17","unstructured":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol. Executive summary: A report of the American college of cardiology\/American heart association task force on clinical practice guidelines | Circulation n.d.(accessed December 10, 2024). https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIR.0000000000000624?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org"},{"key":"7883_CR18","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1161\/01.CIR.90.4.1679","volume":"90","author":"CD Furberg","year":"1994","unstructured":"Furberg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid artery progression study (ACAPS) Research Group. Circulation. 1994;90:1679\u201387. https:\/\/doi.org\/10.1161\/01.CIR.90.4.1679.","journal-title":"Circulation"},{"key":"7883_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301\u20138. https:\/\/doi.org\/10.1056\/NEJM199511163332001.","journal-title":"N Engl J Med"},{"key":"7883_CR20","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS\/TexCAPS. JAMA. 1998;279:1615\u201322. https:\/\/doi.org\/10.1001\/jama.279.20.1615.","journal-title":"JAMA"},{"key":"7883_CR21","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288:2998\u20133007. https:\/\/doi.org\/10.1001\/jama.288.23.2998.","journal-title":"JAMA"},{"key":"7883_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(03)12948-0.","journal-title":"Lancet"},{"key":"7883_CR23","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","volume":"361","author":"H Holdaas","year":"2003","unstructured":"Holdaas H, Fellstr\u00f6m B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(03)13638-0.","journal-title":"Lancet"},{"key":"7883_CR24","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","volume":"108","author":"ER Mohler","year":"2003","unstructured":"Mohler ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481\u20136. https:\/\/doi.org\/10.1161\/01.CIR.0000090686.57897.F5.","journal-title":"Circulation"},{"key":"7883_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(04)16895-5.","journal-title":"Lancet"},{"key":"7883_CR26","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","volume":"110","author":"FW Asselbergs","year":"2004","unstructured":"Asselbergs FW, Diercks GFH, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809\u201316. https:\/\/doi.org\/10.1161\/01.CIR.0000146378.65439.7A.","journal-title":"Circulation"},{"key":"7883_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jacc.2005.02.089","volume":"46","author":"C Vitamin","year":"2005","unstructured":"Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, vitamin E. The St. Francis heart study randomized clinical trial. J Am Coll Cardiol. 2005;46:166\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2005.02.089.","journal-title":"J Am Coll Cardiol"},{"key":"7883_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.atherosclerosis.2004.08.033","volume":"178","author":"SA Anderssen","year":"2005","unstructured":"Anderssen SA, Hjelstuen AK, Hjermann I, et al. Fluvastatin and lifestyle modification for reduction of carotid intima\u2013media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis. 2005;178:387\u201397. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.08.033.","journal-title":"Atherosclerosis"},{"key":"7883_CR29","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2337\/dc05-2415","volume":"29","author":"RH Knopp","year":"2006","unstructured":"Knopp RH, d\u2019Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478\u201385. https:\/\/doi.org\/10.2337\/dc05-2415.","journal-title":"Diabetes Care"},{"key":"7883_CR30","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","volume":"368","author":"H Nakamura","year":"2006","unstructured":"Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(06)69472-5.","journal-title":"Lancet"},{"key":"7883_CR31","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med"},{"key":"7883_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000215939","volume":"28","author":"VCT Mok","year":"2009","unstructured":"Mok VCT, Lam WWM, Chen XY, et al. Statins for asymptomatic middle cerebral artery stenosis: The regression of cerebral artery stenosis study. Cerebrovasc Dis. 2009;28:18\u201325. https:\/\/doi.org\/10.1159\/000215939.","journal-title":"Cerebrovasc Dis"},{"key":"7883_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","volume":"121","author":"KL Chan","year":"2010","unstructured":"Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis. Circulation. 2010;121:306\u201314. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.900027.","journal-title":"Circulation"},{"key":"7883_CR34","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1600176.","journal-title":"N Engl J Med"},{"key":"7883_CR35","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2337\/dc17-2224","volume":"41","author":"H Itoh","year":"2018","unstructured":"Itoh H, Komuro I, Takeuchi M, et al. Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: Report of a randomized study. Diabetes Care. 2018;41:1275\u201384. https:\/\/doi.org\/10.2337\/dc17-2224.","journal-title":"Diabetes Care"},{"key":"7883_CR36","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/art.40892","volume":"71","author":"GD Kitas","year":"2019","unstructured":"Kitas GD, Nightingale P, Armitage J, et al. A Multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1437\u201349. https:\/\/doi.org\/10.1002\/art.40892.","journal-title":"Arthritis Rheumatol"},{"key":"7883_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijcard.2020.01.006","volume":"305","author":"M Moroi","year":"2020","unstructured":"Moroi M, Nagayama D, Hara F, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol. 2020;305:139\u201346. https:\/\/doi.org\/10.1016\/j.ijcard.2020.01.006.","journal-title":"Int J Cardiol"},{"key":"7883_CR38","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/eurheartj\/ehab919","volume":"43","author":"S Merat","year":"2022","unstructured":"Merat S, Jafari E, Radmard AR, et al. Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. Eur Heart J. 2022;43:2023\u201333. https:\/\/doi.org\/10.1093\/eurheartj\/ehab919.","journal-title":"Eur Heart J"},{"key":"7883_CR39","doi-asserted-by":"publisher","first-page":"e067910","DOI":"10.1136\/bmjopen-2022-067910","volume":"13","author":"T Shah","year":"2023","unstructured":"Shah T, McCarthy M, Nasir I, et al. Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open. 2023;13:e067910. https:\/\/doi.org\/10.1136\/bmjopen-2022-067910.","journal-title":"BMJ Open"},{"key":"7883_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000528763","volume":"52","author":"C Hamada","year":"2023","unstructured":"Hamada C, Okuda M, Tomino Y. Pitavastatin compared with differential intervention trial by standard therapy on cardiovascular events in patients with dyslipidemia on chronic hemodialysis (DIALYSIS): A randomized controlled trial. Blood Purif. 2023;52:483\u201392. https:\/\/doi.org\/10.1159\/000528763.","journal-title":"Blood Purif"},{"key":"7883_CR41","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389:687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2304146.","journal-title":"N Engl J Med"},{"key":"7883_CR42","doi-asserted-by":"publisher","unstructured":"Zheng H, Li H, Wang Y, et al. Rosuvastatin slows progression of carotid intima-media thickness: The METEOR-China randomized controlled study. Stroke 2022;53:3004\u201313. https:\/\/doi.org\/10.1161\/STROKEAHA.120.031877","DOI":"10.1161\/STROKEAHA.120.031877"},{"key":"7883_CR43","doi-asserted-by":"publisher","unstructured":"Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;2013:CD004816. https:\/\/doi.org\/10.1002\/14651858.CD004816.pub5","DOI":"10.1002\/14651858.CD004816.pub5"},{"key":"7883_CR44","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM198904063201405","volume":"320","author":"H Iso","year":"1989","unstructured":"Iso H, Jacobs DR, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904\u201310. https:\/\/doi.org\/10.1056\/NEJM198904063201405.","journal-title":"N Engl J Med"},{"key":"7883_CR45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/ije\/dyg106","volume":"32","author":"X Zhang","year":"2003","unstructured":"Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32:563\u201372. https:\/\/doi.org\/10.1093\/ije\/dyg106.","journal-title":"Int J Epidemiol"},{"key":"7883_CR46","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"CB Newman","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: A scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2019;39:e38\u201381. https:\/\/doi.org\/10.1161\/ATV.0000000000000073.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7883_CR47","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(16)30962-X","volume":"389","author":"GJ Hankey","year":"2017","unstructured":"Hankey GJ, Stroke. Lancet. 2017;389:641\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(16)30962-X.","journal-title":"Lancet"},{"key":"7883_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","volume":"5","author":"BCV Campbell","year":"2019","unstructured":"Campbell BCV, De Silva DA, Macleod MR, et al. Ischaemic stroke. Nat Rev Dis Primers. 2019;5:70. https:\/\/doi.org\/10.1038\/s41572-019-0118-8.","journal-title":"Nat Rev Dis Primers"},{"key":"7883_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1747493019873594","volume":"15","author":"H Milionis","year":"2020","unstructured":"Milionis H, Ntaios G, Korompoki E, et al. Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview. Int J Stroke. 2020;15:377\u201384. https:\/\/doi.org\/10.1177\/1747493019873594.","journal-title":"Int J Stroke"},{"key":"7883_CR50","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","volume":"76","author":"S Kr\u00e4henb\u00fchl","year":"2016","unstructured":"Kr\u00e4henb\u00fchl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: When statins won\u2019t. Do! Drugs. 2016;76:1175\u201390. https:\/\/doi.org\/10.1007\/s40265-016-0613-0.","journal-title":"Do! Drugs"},{"key":"7883_CR51","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/ APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: Executive summary. Circulation 2019;139:e1082\u2013143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625","DOI":"10.1161\/CIR.0000000000000625"},{"key":"7883_CR52","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH, et al. Sequence variations in PCSK9, Low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372. https:\/\/doi.org\/10.1056\/NEJMoa054013.","journal-title":"N Engl J Med"},{"key":"7883_CR53","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","volume":"65","author":"BA Ference","year":"2015","unstructured":"Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both. J Am Coll Cardiol. 2015;65:1552\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2015.02.020.","journal-title":"J Am Coll Cardiol"},{"key":"7883_CR54","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA. 2016;316:1289\u201397. https:\/\/doi.org\/10.1001\/jama.2016.13985.","journal-title":"JAMA"},{"key":"7883_CR55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"7883_CR56","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","volume":"6","author":"H Naci","year":"2013","unstructured":"Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins. Circulation: Cardiovasc Qual Outcomes. 2013;6:390\u20139. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.111.000071.","journal-title":"Circulation: Cardiovasc Qual Outcomes"},{"key":"7883_CR57","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41587-022-01520-x","volume":"41","author":"RL Alles\u00f8e","year":"2023","unstructured":"Alles\u00f8e RL, Lundgaard AT, Hern\u00e1ndez Medina R, et al. Discovery of drug\u2013omics associations in type 2 diabetes with generative deep-learning models. Nat Biotechnol. 2023;41:399\u2013408. https:\/\/doi.org\/10.1038\/s41587-022-01520-x.","journal-title":"Nat Biotechnol"},{"key":"7883_CR58","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(05)66378-7.","journal-title":"Lancet"},{"key":"7883_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/cvr\/cvt070","volume":"99","author":"N Hermida","year":"2013","unstructured":"Hermida N, Markl A, Hamelet J, et al. HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovasc Res. 2013;99:44\u201354. https:\/\/doi.org\/10.1093\/cvr\/cvt070.","journal-title":"Cardiovasc Res"},{"key":"7883_CR60","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jacc.2011.09.067","volume":"59","author":"WJ Kostis","year":"2012","unstructured":"Kostis WJ, Cheng JQ, Jeanne MD, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2011.09.067.","journal-title":"J Am Coll Cardiol"},{"key":"7883_CR61","unstructured":"Zoungas S. A Study of STAtins for reducing events in the elderly (STAREE). clinicaltrials.gov; 2024."},{"key":"7883_CR62","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2018.2525","volume":"319","author":"EP Navarese","year":"2018","unstructured":"Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering. JAMA. 2018;319:1566\u201379. https:\/\/doi.org\/10.1001\/jama.2018.2525.","journal-title":"JAMA"},{"key":"7883_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12874-021-01310-0","volume":"21","author":"M Geissb\u00fchler","year":"2021","unstructured":"Geissb\u00fchler M, Hincapi\u00e9 CA, Aghlmandi S, et al. Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study. BMC Med Res Methodol. 2021;21:123. https:\/\/doi.org\/10.1186\/s12874-021-01310-0.","journal-title":"BMC Med Res Methodol"},{"key":"7883_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jclinepi.2017.03.015","volume":"89","author":"P Geldsetzer","year":"2017","unstructured":"Geldsetzer P, Fawzi W. Quasi-experimental study designs series\u2014paper 2: complementary approaches to advancing global health knowledge. J Clin Epidemiol. 2017;89:12\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.03.015.","journal-title":"J Clin Epidemiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07883-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07883-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07883-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:29:22Z","timestamp":1789522162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07883-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7883"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07883-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human Ethics and Consent to Participate declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}